Abstract: Type 2 diabetes mellitus (T2DM) and cardiovascular diseases are common chronic progressive diseases with high morbidity and mortality. They are often connected with each other and affect the progress of disease course. With the course of disease， and the reduction of pancreatic islet function， it is difficult for traditional hypoglycemic agents to control blood glucose radically， and it appears some adverse effects such as gaining weight or hypoglycemia， while the accompany of cardiovascular diseases increase the difficulty of the treatment of T2DM. As a new type of oral glucose-lowering drugs， sodium-glucose cotransporter 2 (SGLT2) inhibitor solves the problem above effectively， safely and conveniently， it also reduces the risk of hypoglycaemia， it plays a role of reducing weight， regulating blood lipid， lowering blood pressure， protecting heart function， and even reducing the risk of cardiovascular death， so the SGLT2 inhibitors have broad application in the field of diabetic cardiovascular disease. However， the safety of the drug in patients who have diabetes mellitus with cardiovascular disease needs cautious.